Imatinib-responsive hypereosinophilia in a patient with B cell ALL.
Hypereosinophilia is a rare presenting sign of acute lymphocytic leukemia. A 29-year-old male was diagnosed with idiopathic hypereosinophilic syndrome with respiratory symptoms. Although his peripheral blood eosinophilia decreased in response to treatment with imatinib mesylate, a follow-up bone marrow showed a diffuse infiltrate of myeloperoxidase-negative blasts. He was subsequently diagnosed with CD10 positive precursor B lymphoblastic leukemia. This case underscores the importance of follow-up bone marrow examination in patients who demonstrate imatinib mesylate-responsive eosinophilia.
Robyn
Jamie
J
Hematology Branch, National Heart Lung and Blood Institute National Institutes of Health Bethesda, MD 20892, USA. robynj@nih.gov
Noel
Pierre
P
Wlodarska
Iwona
I
Choksi
Mamta
M
O'neal
Patricia
P
Arthur
Diane
D
Dunbar
Cynthia
C
Nutman
Thomas
T
Klion
Amy
A
D000328:Adult; D001549:Benzamides; D002051:Burkitt Lymphoma / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D004804:Eosinophils / Q000473:pathology; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D000068877:Imatinib Mesylate; D007958:Leukocyte Count; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate